Abstract
We evaluated the association between the XPD exon 10 Asp(312)Asn and exon 23 Lys(751)Gln polymorphisms and the risk of pancreatic cancer in a hospital-based study of 344 patients and 386 controls frequency matched by age, gender, and race. Stratified analyses showed ever smokers carrying the Asn(312)Asn genotype had a significantly reduced risk when compared with those carrying the (312)Asp allele (OR=0.46, 95% confidence interval 0.24-0.88) (P for interaction=0.03). The (312)Asp-(751)Gln was identified as the putative at risk haplotype. Our study shows that the XPD gene polymorphism could be a genetic risk modifier for smoking-related pancreatic cancer.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adenocarcinoma / etiology
-
Adenocarcinoma / genetics
-
Adenocarcinoma / pathology
-
Aged
-
Amino Acid Substitution
-
Asparagine / genetics
-
Aspartic Acid / genetics
-
Carcinoma, Pancreatic Ductal / etiology
-
Carcinoma, Pancreatic Ductal / genetics
-
Carcinoma, Pancreatic Ductal / pathology
-
Case-Control Studies
-
Female
-
Gene Frequency
-
Genotype
-
Glutamine / genetics
-
Haplotypes*
-
Humans
-
Linkage Disequilibrium
-
Lysine / genetics
-
Male
-
Middle Aged
-
Pancreatic Neoplasms / etiology
-
Pancreatic Neoplasms / genetics*
-
Pancreatic Neoplasms / pathology
-
Polymorphism, Single Nucleotide*
-
Risk Factors
-
Smoking / adverse effects
-
Xeroderma Pigmentosum Group D Protein / genetics*
Substances
-
Glutamine
-
Aspartic Acid
-
Asparagine
-
Xeroderma Pigmentosum Group D Protein
-
Lysine